BDTX-189 manufacturers
- Tuxobertinib
-
- $55.00
-
2026-07-27
- CAS:2414572-47-5
- Purity: 99.22%
- Supply Ability: 10g
- BDTX-189
-
-
2026-07-07
- CAS:2414572-47-5
- Min. Order: 1KG
- Purity: 98%
- Supply Ability: 1000kg
|
| | BDTX-189 Basic information |
| Product Name: | BDTX-189 | | Synonyms: | BDTX-189;2-Propenamide, N-[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-7-[2-(4-morpholinyl)ethoxy]-6-quinazolinyl]-;Tuxobertinib,inhibit,ErbB-1,EGFR,BDTX 189,BDTX189,mutants,Epidermal growth factor receptor,nude,allosteric,Ba/F3,HER1,oncogene athymic,oral,mice,insertion,Inhibitor;EGFR/HER2 inhibitor BDTX-189;ErbB mutant-specific inhibitor BDTX-189;Tuxobertinib (BDTX-189);Bugatinib;N-(4-((3-Chloro-4-(pyridin-2-ylmethoxy)phenyl)amino)-7-(2-morpholinoethoxy)quinazolin-6-yl)acrylamide | | CAS: | 2414572-47-5 | | MF: | C29H29ClN6O4 | | MW: | 561.03 | | EINECS: | | | Product Categories: | API;APIs | | Mol File: | 2414572-47-5.mol |  |
| | BDTX-189 Chemical Properties |
| Boiling point | 778.0±60.0 °C(Predicted) | | density | 1.349±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO:22.56(Max Conc. mg/mL);40.21(Max Conc. mM)
DMF:1.0(Max Conc. mg/mL);1.78(Max Conc. mM)
DMF:PBS (pH 7.2) (1:2):0.3(Max Conc. mg/mL);0.53(Max Conc. mM) | | form | A solid | | pka | 12.20±0.43(Predicted) | | color | Off-white to light yellow | | InChIKey | HIBPKFXWOPYJPZ-UHFFFAOYSA-N | | SMILES | C(NC1C(OCCN2CCOCC2)=CC2C(C=1)=C(NC1=CC=C(OCC3=NC=CC=C3)C(Cl)=C1)N=CN=2)(=O)C=C |
| | BDTX-189 Usage And Synthesis |
| Uses | Tuxobertinib (BDTX-189) is a potent, orally active and selective inhibitor of allosteric EGFR and HER2 oncogenic mutations, including EGFR/HER2 exon 20 insertion mutants. Tuxobertinib shows KDs of 0.2, 0.76, 13 and 1.2 nM for EGFR, HER2, BLK and RIPK2, reapectively. Anticancer activity[1]. | | in vivo | Tuxobertinib (0-100 mg/kg; p.o.; daily for 15 dyas) shows dose-dependent tumor growth inhibition and regression in in athymic nude mice bearing HER2 S310F Ba/F3 allograft tumors[1].
Tuxobertinib (1-50 mg/kg.p.o.; daily for 15 days) shows dose-dependent tumor growth inhibition and regression in athymic nude mice bearing CUTO-14 PDX tumors that express the EGFR mutation EGFR ASV[1]. | | IC 50 | EGFR: 0.2 nM (Kd); HER2: 0.76 nM (Kd); RIPK2: 1.2 nM (Kd); BLK: 13 nM (Kd) | | References | [1] Elizabeth Buck, et al. BDTX-189, a Potent and Selective Inhibitor of Allosteric EGFR and HER2 Oncogenic Mutations. |
| | BDTX-189 Preparation Products And Raw materials |
|